Olema Pharmaceuticals, Inc. OLMA Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -36.6%+2.5pp | -39.1%+3.8pp | -42.8%+0.6pp | -43.5%-20.6pp | |
| Return on assets | -33%+2.6pp | -35.6%+3.7pp | -39.2%+1.7pp | -41%-18.7pp | |
| Return on invested capital | -50.9%+11.1pp | -62%-4.4pp | -57.6%-10.1pp | -47.5%— | |
| Liquidity | |||||
| Current ratio | 10×-0.5× | 10.5×-1.8× | 12.3×-0.3× | 12.6×-19.6× | |
| Quick ratio | 10×-0.5× | 10.5×-1.8× | 12.3×-0.3× | 12.6×-19.6× | |
| Cash ratio | 0.9×-2.4× | 3.3×+0.2× | 3.2×+1.7× | 1.4×-0.1× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $5.50-21.0% | $6.96+24.1% | $5.61+13.6% | $4.94-31.4% | |
| Valuation | |||||
| Market capitalization | $998.38M+253% | $430.29M-44.0% | $768.62M+681% | $98.46M-73.6% | |
| Enterprise value | $946.79M+306% | $292.24M-58.4% | $702.5M+809% | $77.32M-78.7% | |
| Price / book | 2.1×+1.3× | 1.1×-2.0× | 3×+2.5× | 0.5×-0.8× | |
| Earnings yield | -18.5%+27.1pp | -30.1%-17.5pp | -12.6%+93.8pp | -106.4%-87.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Olema Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Olema Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.